Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
NovoCure
NVCR
NovoCure
Regulatory Delays And Setbacks Will Restrict Adoption Yet Allow Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
06 Aug 25
Updated
06 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$14.50
19.9% undervalued
intrinsic discount
06 Aug
US$11.62
Loading
1Y
-38.6%
7D
1.0%
Author's Valuation
US$14.5
19.9% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$14.5
19.9% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-174m
763m
2014
2017
2020
2023
2025
2026
2028
Revenue US$762.7m
Earnings US$95.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
12.50%
Medical Equipment revenue growth rate
0.31%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.29%
Calculation
US$95.26m
Earnings '28
x
23.77x
PE Ratio '28
=
US$2.26b
Market Cap '28
US$2.26b
Market Cap '28
/
123.27m
No. shares '28
=
US$18.37
Share Price '28
US$18.37
Share Price '28
Discounted to 2025 @ 8.29% p.a.
=
US$14.47
Fair Value '25
